Drug Database
HO

Hoe-285 (Hoe 285 / Brainorm / Albex 285)

✓ Approved

Sanofi S.A · Small Molecule · Small Molecule

What is Hoe-285?

Hoe-285 is a small molecule developed by Sanofi S.A. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or oral (po).

Drug Profile

Brand NamesHoe 285, Brainorm, Albex 285
CompanySanofi S.A
Drug ClassSmall Molecule
RouteInjectable (Others), Intravenous (IV), Oral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Sanofi S.A

Therapeutic Indications

Hoe-285 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersDelayed ischaemic neurological deficit✓ Approved

Related Research Articles

PubMedFrontiers in nutrition2026-07-17

Using digital technology to ensure food supply stability: a case study of achieving food security in China.

Wei Danqi D

Under the combined pressures of frequent extreme climate events and the spread of unilateral trade policies, global agricultural industry and supply chains are facing an unprecedented crisis. Digital technology (DT) is a key driver of the new technological revolution and is profoundly reshaping food production, distribution, and consumption. However, its comprehensive impact on food security and the underlying mechanisms remain unclear. This study systematically elaborates the theoretical logic through which digital technology enhances food security. Using panel data from 285 prefecture-level cities in China from 2011 to 2024, we construct an innovative urban DT composite index based on the number of artificial intelligence patents and the coverage rate of digital infrastructure. A dynamic spatial Durbin model and a mediation effects model are employed for empirical testing. The findings reveal three main results. First, DT has a significant direct positive effect on urban food security and a significant positive spatial spillover effect, meaning that local DT development improves food security in neighboring regions. These results remain robust after using instrumental variable methods, substituting core variables, and performing multiple robustness checks. Second, the mechanism analysis shows that DT indirectly enhances food security by improving agricultural socialized services, accelerating land transfer efficiency, and reducing climate-induced volatility in agricultural production. Among these channels, agricultural socialized services have the strongest mediating effect. Third, heterogeneity analysis indicates that the enabling effect of DT on food security is more pronounced in non-major grain-producing areas, regions with flat terrain, and cities with higher levels of financial development, suggesting that DT helps bridge the digital divide in agricultural development across regions. This study deepens the understanding of food security mechanisms in the digital economy era and provides a solid theoretical and empirical foundation for formulating precise, differentiated policies for digital villages and smart agriculture, thereby supporting the development of new-quality productivity in agriculture.

PMID 42466139
Read full article →
PubMedInternational journal of clinical pharmacy2026-07-17

Collaborative pharmacist prescribing in community heart failure clinics: a pre-post intervention comparison.

Percival Matthew M, Hattingh Laetitia L, Jayasinghe Rohan R, Millhouse James J et al.

Guideline-directed medical therapy (GDMT) improves outcomes in heart failure, yet many patients remain undertreated or are not titrated to optimal doses. International evidence shows pharmacist-led heart failure clinics improve GDMT prescribing and reduce hospitalisations, but data in Australian settings are limited. To evaluate whether incorporating a collaborative pharmacist medication prescribing model within a heart failure service improved optimisation of guideline-directed medical therapy (GDMT) in patients with heart failure and ejection fraction < 50% compared with pre-implementation usual care, and to evaluate impacts on service efficiency, hospitalisation, mortality, medication beliefs, and health-related quality of life. An interrupted time series analysis compared 12-month pre- and post-implementation periods following establishment of a collaborative pharmacist medication prescribing clinic across two community heart failure services. Primary outcomes were the proportion of patients optimised on GDMT at 90 days and at clinic discharge. Secondary outcomes included time between visits, monthly attendance, unscheduled hospitalisations, medication adherence and health related quality of life (HRQoL) assessed with the EuroQoL five-dimension five-level health status instrument visual analogue scale (EQ-VAS) and the Kansas City Cardiomyopathy Questionnaire (KCCQ-12). A total of 302 patients with ejection fraction < 50% were included, with 98 and 204 patients in the pre- and post-implementation cohort respectively. Overall, 285 patients (94.4%) had a left ventricular ejection fraction ≤ 40%, with similar proportions between cohorts (94.6% vs. 93.9%; p = 1.000). Optimisation of GDMT increased from 19.3% (n = 19) to 40.2% (n = 82) at 90 days (adjusted OR = 2.6, p = 0.001), and from 43.9% (n = 43) to 88.2% (n = 180) at discharge (adjusted OR = 13.2, p < 0.001). Median time between visits decreased from 49 to 28 days (p < 0.001), while mean monthly attendance increased from 9 to 16 (p < 0.001). HRQoL scores increased within the post-implementation group, measured by the KCCQ-12 (74.0 → 84.8, p < 0.001) and EQ-VAS (73.0 → 79.5, p = 0.004). Medication adherence remained high according to self-reported Medication Adherence Report Scale (MARS) scores. No change in hospitalisations or mortality was observed. Introducing a collaborative pharmacist medication prescribing clinic to usual care was associated with higher rates of GDMT optimisation and increased clinic throughput. These findings support the feasibility of collaborative prescribing models to facilitate GDMT optimisation within Australian health services.

PMID 42467354
Read full article →
PubMedAdvances in neonatal care : official journal of the National Association of Neonatal Nurses2026-07-16

Thermal Stability of Extremely Preterm Infants During Early Kangaroo Mother Care in the First 5 Days of Life.

Collados-Gómez Laura L, Solaz-García Álvaro Á, Jimenez-Fernández Lucía L, Piris-Borregas Salvador S et al.

Extremely preterm infants are highly vulnerable to hypothermia because of immature thermoregulation and increased heat loss. Kangaroo mother care (KMC) is an evidence-based intervention associated with improved thermal stability, but evidence in extremely preterm infants during the first days of life remains limited. To evaluate axillary temperature 60 minutes after initiating KMC in infants <28 weeks' gestation during the first 5 days of life, analyze temperature trends across sessions, and identify factors associated with thermal stability. This prospective observational study was conducted as a secondary analysis of a noninferiority randomized controlled trial. Seventy extremely preterm infants admitted to a Level IIIC Neonatal Intensive Care Unit were included. Axillary temperature was measured at 5 time points during each KMC session, with the primary outcome assessed at 60 minutes. Seventy infants (mean gestational age 26 weeks) participated in 285 KMC sessions during the first 5 days of life. Infants maintained normothermia, with a mean axillary temperature of 36.83°C at 60 minutes. Temperature stability followed a cubic trend over time, with no differences by session order. A slight temperature decrease occurred during the first session, whereas subsequent sessions showed temperature increases. Environmental variables were not associated with thermal stability. Early KMC is safe and effective for maintaining thermal stability in extremely preterm infants, including those with central lines. Attention during return transfer is essential to minimize heat loss. Larger studies are needed to confirm these findings and optimize early KMC protocols.

PMID 42462083
Read full article →
PubMedNeurogastroenterology and motility2026-07-16

Provider-Prescribed Restrictive Diets in Patients With Eating Disorders Presenting for Gastroenterology Care.

Amini Armand A, Dekel Mia M, Almeida Mariana N MN, Atkins Micaela M et al.

Despite considerable evidence and patient demand, restrictive diets for gastrointestinal (GI) disorders may be harmful in those with comorbid eating disorders (EDs). We identified the frequency and characteristics of provider-recommended restrictive diets among those with EDs seeking GI care. Using a preexisting cohort of patients who had a GI encounter from 2010 to 2020 with a GI diagnosis and ED diagnosis (either diagnosed before or after initial GI encounter), we conducted a retrospective analysis of restrictive diet prescriptions within 12 months of initial GI consult as well as diet type, provider subspecialty, and types of ED and GI diagnoses. From a cohort of 610 patients, we found 285 patients meeting our inclusion criteria; 50 (17.5%) were prescribed restrictive diets within 12 months of their GI consult by GI providers. Disorders of gut-brain interaction were the most common GI diagnoses overall (n = 169, 59.3%). Of those with a pre-existing ED (n = 188), 30 (16.0%) were prescribed a restrictive diet, and of those with a subsequently diagnosed ED (n = 97), 20 (20.6%) were prescribed a restrictive diet. Among patients with preexisting EDs, 69 (36.7%) were not in remission at the time of consultation. Of those with preexisting EDs who were prescribed a restrictive diet, 17/30 (57.7%) were not in remission. We found that 16% of patients with an ED history were prescribed a restrictive diet by their gastroenterologist, including those not in remission. Further research is needed on the potential risk of restrictive diets in facilitating ED behavior.

PMID 42458684
Read full article →
PubMedDermatology and therapy2026-07-16

Understanding Social Drivers of Health Among US Adults with Psoriasis from Different Races and Ethnicities.

Barbosa Victoria V, Bhutani-Jacques Tina T, Callender Valerie D VD, Bacci Elizabeth D ED et al.

Psoriasis, a chronic immune-mediated inflammatory skin condition with systemic implications and substantial psychosocial burden, affects individuals across races and ethnicities. This study explored social drivers of health (SDOH), disease burden, and the impact of psoriasis across races and ethnicities. An online, cross-sectional survey was conducted among adult US patients with psoriasis (September-December 2023). Participants were recruited through the National Psoriasis Foundation and AmeriSpeak, a national sample panel. Descriptive data were collected using patient-reported outcome measures and questions on disease knowledge, healthcare access and utilization, quality of life (QoL), and social impact. Analyses were stratified by races and ethnicities. Among 285 participants (mean age 46.7 years; 50.9% male), 68.1% identified as white, 19.3% as Black/African American (BAA), and 20.4% as Hispanic/Latino (H/L). Overall, psoriasis severity was reported as moderate by 36.8% (white: 37.6%, BAA: 25.5%, Asian: 50.0%, and H/L: 27.6%) and severe by 10.2% (white: 8.2%, BAA: 10.9%, Asian: 20.0%, and H/L: 6.9%) of patients. Participants reported moderate QoL impact (Dermatology Life Quality Index [DLQI] mean 10.3), with high burden among H/L (16.6) and BAA (15.1) groups. During flares, 58.6% used prescription medications, with similar rates across races and ethnicities. Transportation barriers were reported by 21.4% overall, more commonly reported by H/L (44.8%) and BAA (34.5%) participants. Difficulty accessing medicine/healthcare was reported by 26.3% overall, particularly white (29.4%) participants. Overall, 29.1% delayed care owing to cultural/linguistic differences, most commonly by BAA and H/L groups. Of the healthcare services requiring partial out-of-pocket payment for treatment of psoriasis, medications were reported as the highest burden by an overall 47.0% of patients (H/L: ~55%, white and BAA ~45%). Overall, only 29.5% received financial assistance. In this descriptive survey, patients perceived psoriasis as a considerable burden across races and ethnicities. Understanding diversities in patient-reported SDOH and healthcare access issues through culturally competent integrated care may potentially optimize psoriasis outcomes.

PMID 42458187
Read full article →
PubMedMolecular genetics & genomic medicine2026-07-15

The Pathogenicity Analysis of a Hypogonadotropic Hypogonadism Patient With the Novel Variant in the Deep Intronic Region of the PROK2 Gene.

Chen Jiali J, Ma Yujin Y, Li Liping L, Peng Huifang H et al.

Isolated hypogonadotropic hypogonadism (IHH) is a rare endocrine disorder caused by genes such as ANOSI (OMIM*300836), FGFR1 (OMIM*136350), PROK2 (OMIM*607002) and PROKR2 (OMIM*607123) (etc.), leading to downstream dysfunction of pituitary gonadotropin secretion and subsequent impairment of gonadal function. Clinical manifestations include incomplete or partial puberty and infertility. In this study, whole-genome sequencing of a female patient with HH identified a novel 5' splice site variant c.285 + 772 T>G in the deep intron of PROK2 (NM_001126128.2). In vitro minigene validation revealed abnormal splicing of this variant, with 69 base pairs retained in intron 3, ultimately leading to changes in protein length, which may lead to changes in protein structure. According to the American College of Medical Genetics and Genomics (ACMG) pathogenicity classification, this variant is rated as likely pathogenic variant (LP). PROK2 variants can lead to HH and we report a case with a novel splice site variant that has been confirmed to lead to the retention of 69 base pairs in intron 3 during RNA splicing.

PMID 42449499
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Hoe-285